Abstract
Pricing and reimbursement policies have changed significantly in Russia during the last 20 years, largely due to ongoing reform processes within the healthcare system. The current structure of the Russian healthcare system includes federal and regional levels with different requirements and funding allocations due to diversity in the population (average and population density), overall and per capita income, and other factors. The federal level is governed by the Federal Ministry of Health, which is responsible for the pricing and reimbursement policies in the country. Federal budgeting covers the majority of healthcare programs, while the regional budget provides additional financing for regional needs. Reimbursement of drugs is incorporated in these programs, along with other expenses (hospitalization, laboratory testing, and so forth).
In terms of pharmaceutical policy, inclusion of medicines into reimbursement lists includes two staged steps in Russia. In the first step, the drug must be included in the Essential Drug List (EDL) and a pricing cap is then applied. The upper margin of the drug price is determined as a referral price for imported medicines (based on a basket of 21 countries). It can also be based on drug development and manufacturing expenses and include regional markups specified for each region. Cost-effectiveness analysis is part of the requirement for submission of an EDL dossier in Russia. The second step in the process is the inclusion of EDL-listed drugs into federal healthcare disease specific programs (oncology, HIV, and so forth). Regions can establish healthcare programs in addition to the federal activity based on regional requirements and their own regional funding allocations and budgets. There are different needs within the healthcare system at federal and regional levels; including hospital and industrial corporations who have their own healthcare services. This can contribute to challenges in implementation of uniform approaches to Health Technology Assessment (HTA) at different levels and in the different regions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Federal State Statistics Service. Russian Federation. http://www.gks.ru
Petrovsky, B. P. (Chief Editor). (1977). 60 years of the soviet healthcare system. – M.: Medicine, (p. 416) (in Russian).
Zabludovsky, P. E., Kruchok, G. R., Kuzmin, M. K., & Levit, M. M. (1981). History of medicine. – M.: Medicine, (p. 285–351) (in Russian).
Russian Federal law from 30.12.2015 No. 432-FZ “On amendments to article 25 of the Law of the Russian Federation “On organization of insurance business in the Russian Federation” and Federal law “On mandatory medical insurance in the Russian Federation”. https://rg.ru/2016/01/11/strahovaniye-dok.html
Russian Federal law of November 21, 2011 N 323-FZ “About bases of health protection of citizens in the Russian Federation”. https://rg.ru/2011/11/23/zdorovie-dok.html
Sokolova S. V., Orlov A. S., & Rumyanceva M. S.. (2013). The pharmaceutical market: public procurement of medicines. Problems of modern economics. 2013. #4. pp. 345–349. http://cyberleninka.ru/article/n/farmatsevticheskiy-rynok-gosudarstvennye-zakupki-lekarstvennyh-preparatov
Ministry of Health. Russian Federation. https://www.rosminzdrav.ru
Drug Store Monitoring Analytical Agency. www.dsm.ru
Clinical protocols. Oncology. http://www.oncology.ru/russco/.
Russian Information and analytical weekly “Auctionvestnic”. http://auctionvestnik.ru/node/256
Russian Federation Government resolution from February 17, 2011 N 91 “About the Federal target program “Development of pharmaceutical and medical industry of the Russian Federation for the period till 2020 and the further prospect” http://www.consultant.ru/document/cons_doc_LAW_111638/”
Russian Federal law from 01.06.2012 No. 761-FZ “On National Strategy for actions in children interests 2012–2017”. http://base.garant.ru/70183566/
The Russian Federation Government resolution from February 17, 2011 N 91 “About the Federal target program “Development of pharmaceutical and medical industry of the Russian Federation for the period till 2020 and further perspective” (with changes and additions)”
Russian Federal law dated 12 April 2010 N 61-FZ “On circulation of medicines” (with amendments and additions). https://rg.ru/2010/04/14/lekarstva-dok.html
The decree 214 of the Russian Federation Government dated 12 March 2015 N 214 “About approval of Rules of granting in 2015 subsidies from the Federal budget to the organizations of industry for reimbursement of expenses incurred in 2015 for interest payment on credits obtained in Russian credit institutions and state Corporation “Bank for development and foreign economic Affairs (Vnesheconombank)”, as well as in the international financial organizations created under international treaties which participants are the Russian Federation, for working capital and (or) the financing of current production activity” (with changes and additions). http://base.garant.ru/70889986/
National Research Institution for Public Health. www.nriph.ru
Russian Research and Investigate Institution for Medical Devices. http://vniiimt.org
Federal Service for Surveillance in Healthcare (Roszdravnadzor). http://www.roszdravnadzor.ru/en
Information methodical center on examination, registration and analysis for Medical Devices. http://fgu.ru
Clinical protocols. Hematology. http://npngo.ru/library/guideline/
The decree 871 of the Russian Federation Government of 28 August 2014 N 871 “On approval of Rules of forming of lists of medicinal preparations for medical application and the minimum assortment of medicinal preparations necessary for rendering of medical care”. https://rg.ru/2014/09/01/lekarstva-site-dok.html
The RF Government decree of 15 September 2015 N 979 “On amendments to resolution of the Government of the Russian Federation of 29 October 2010 No. 865 and approval of calculation methods established by drug manufacturers’ maximum ex-works prices for the medicinal preparations included into the list of vital and essential medicinal products, in their state registration and re-registration”. http://base.garant.ru/71192234/
Charter 959 of the Federal Agency of scientific organizations approved by the decree of the Government of the Russian Federation from October 25, 2013. No. 959. https://rg.ru/2013/11/04/fano-site-dok.html
Russian Federal law 44 of 05.04.2013 (as amended on 13.07.2015) “On contract system in procurement of goods, works, services for state and municipal needs” (as amended. and EXT., Preface. effective from 15.09.2015). http://www.consultant.ru/document/cons_doc_LAW_144624/.
The decree 1289 of the Russian Federation from 30.11.2015 No. 1289 “About an establishment of restrictions of access for foreign pharmaceuticals in public procurement”. http://base.garant.ru/70227698/
Clinical protocols. Neonatology. http://neonatology.pro/resursnyiy-tsentr/protokolyi/
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Khabriev, R., Meshkov, D., Bezmelnitsyna, L., Cherkasov, S., Berseneva, E., Scahill, S. (2017). Pharmaceutical Policy in Russia. In: Babar, ZUD. (eds) Pharmaceutical Policy in Countries with Developing Healthcare Systems. Adis, Cham. https://doi.org/10.1007/978-3-319-51673-8_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-51673-8_13
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-51672-1
Online ISBN: 978-3-319-51673-8
eBook Packages: MedicineMedicine (R0)